TriSalus Life Sciences (TLSI) Revenue & Revenue Breakdown
TriSalus Life Sciences Revenue Highlights
Latest Revenue (Y)
$29.43M
Latest Revenue (Q)
$11.21M
TriSalus Life Sciences Revenue by Period
TriSalus Life Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $29.43M | 58.99% |
| 2023-12-31 | $18.51M | 49.31% |
| 2022-12-31 | $12.40M | 47.58% |
| 2021-12-31 | $8.40M | 54.60% |
| 2020-12-31 | $5.43M | - |
TriSalus Life Sciences generated $29.43M in revenue during NA 2024, up 58.99% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
TriSalus Life Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $11.21M | 22.32% |
| 2025-03-31 | $9.17M | 10.97% |
| 2024-12-31 | $8.26M | 12.41% |
| 2024-09-30 | $7.35M | -0.20% |
| 2024-06-30 | $7.36M | 14.05% |
| 2024-03-31 | $6.46M | 12.86% |
| 2023-12-31 | $5.72M | 10.17% |
| 2023-09-30 | $5.19M | 12.60% |
| 2023-06-30 | $4.61M | 54.56% |
| 2023-03-31 | $2.98M | -7.50% |
| 2022-12-31 | $3.23M | -17.77% |
| 2022-09-30 | $3.92M | 36.31% |
| 2022-06-30 | $2.88M | 21.43% |
| 2022-03-31 | $2.37M | -7.64% |
| 2021-12-31 | $2.57M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | - |
TriSalus Life Sciences generated $11.21M in revenue during Q2 2025, up 22.32% compared to the previous quarter, and up 173.66% compared to the same period a year ago.
TriSalus Life Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SGHT | Sight Sciences | $79.87M | $17.51M |
| OWLT | Owlet | $78.10M | $21.10M |
| LNSR | LENSAR | $53.49M | $14.16M |
| RCEL | AVITA Medical | $50.56M | $18.51M |
| MXCT | MaxCyte | $38.63M | $10.39M |
| TLSI | TriSalus Life Sciences | $29.43M | $11.21M |
| RPID | Rapid Micro Biosystems | $28.05M | $7.26M |
| HYPR | Hyperfine | $12.89M | $2.14M |
| PROF | Profound Medical | $10.68M | $2.62M |
| AVR | Anteris Technologies Global | $2.73M | $556.00K |
| FBRX | Forte Biosciences | - | - |